ID   FT2-14
AC   CVCL_XA90
SY   FT 2-14
DR   CCRID; 4201PAT-CCTCC00061
DR   JCRB; IFO50180
DR   Wikidata; Q93557138
RX   DOI=10.1038/nbt1189-1163;
RX   Patent=US5506135;
RX   PubMed=2107601;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2158.
CC   Characteristics: This is a tetradoma, a fusion of two hybridomas.
CC   Monoclonal antibody target: UniProtKB; P02675; Human FGB.
CC   Monoclonal antibody target: UniProtKB; P00750; Human PLAT.
CC   Discontinued: JCRB; IFO50180; probable.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_XA78 ! FIB1-11
HI   CVCL_XA82 ! TPA1-41
CA   Hybridoma
DT   Created: 06-09-19; Last updated: 21-03-23; Version: 5
//
RX   DOI=10.1038/nbt1189-1163;
RA   Kurokawa T., Iwasa S., Kakinuma A.;
RT   "Enhanced fibrinolysis by a bispecific monoclonal antibody reactive to
RT   fibrin and tissue plasminogen activator.";
RL   Biotechnology (N.Y.) 7:1163-1167(1989).
//
RX   Patent=US5506135;
RA   Iwasa S., Kurokawa T., Toyoda Y.;
RT   "Hybrid monoclonal antibodies, their production and use.";
RL   Patent number US5506135, 09-Apr-1996.
//
RX   PubMed=2107601; DOI=10.1016/0049-3848(90)90382-M;
RA   Kurokawa T., Iwasa S., Kakinuma A.;
RT   "Enhancement of fibrinolysis by bispecific monoclonal antibodies
RT   reactive to fibrin and plasminogen activators.";
RL   Thromb. Res. 47 Suppl. 10:83-89(1990).
//